Skip to Content


Active Substance: rosiglitazone / glimepiride
Common Name: rosiglitazone / glimepiride
ATC Code: A10BD04
Marketing Authorisation Holder: SmithKline Beecham Ltd
Active Substance: rosiglitazone / glimepiride
Status: Withdrawn
Authorisation Date: 2006-06-27
Therapeutic Area: Diabetes Mellitus, Type 2
Pharmacotherapeutic Group: Drugs used in diabetes

Therapeutic Indication

AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.

The marketing authorisation for Avaglim has been withdrawn for safety reasons following a decision by the European Commission.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.